Insights into the Classification of Myasthenia Gravis
Overview
Authors
Affiliations
Background And Purpose: Myasthenia gravis (MG) is often categorized into thymoma-associated MG, early-onset MG with onset age <50 years, and late-onset MG with onset age ≥50 years. However, the boundary age of 50 years old between early- and late-onset MG remains controversial, and each category contains further subtypes. We attempted to classify MG from a statistical perspective.
Methods: We analyzed 640 consecutive MG patients using two-step cluster analysis with clinical variables and discrimination analysis, using onset age as a variable.
Results: Two-step cluster analyses categorized MG patients into the following five subtypes: ocular MG; MG with thymic hyperplasia (THMG); generalized anti-acetylcholine receptor antibody (AChR-Ab)-negative MG; thymoma-associated MG; and generalized AChR-Ab-positive (SP) MG without thymic abnormalities. Among these 5 subtypes, THMG showed a distribution of onset age skewed toward a younger age (p<0.01), whereas ocular MG and SPMG without thymic abnormalities showed onset age skewed toward an older age (p<0.001 and p<0.0001, respectively). The other 2 subtypes showed normal distributions. THMG appeared as the main component of early-onset MG, and ocular MG and SPMG without thymic abnormalities as the main components of late-onset MG. Discrimination analyses between THMG and ocular MG and/or SPMG without thymic abnormalities demonstrated a boundary age of 45 years old.
Conclusions: From a statistical perspective, the boundary age between early- and late-onset MG is about 45 years old.
[Clinical course of myasthenia gravis at the department of neurology in Antananarivo Madagascar].
Razafindrasata S, Razafimahefa J, Lemahafaka G, Zodaly N, Tehindrazanarivelo A Pan Afr Med J. 2021; 37:304.
PMID: 33654523 PMC: 7896531. DOI: 10.11604/pamj.2020.37.304.18733.
Akaishi T, Motomura M, Aoki M, Utsugisawa K Ann Transl Med. 2019; 7(Suppl 6):S208.
PMID: 31656787 PMC: 6789369. DOI: 10.21037/atm.2019.06.65.
Massa R, Greco G, Testi M, Rastelli E, Terracciano C, Frezza E J Neurol. 2019; 266(4):982-989.
PMID: 30741378 DOI: 10.1007/s00415-019-09225-z.
Response to treatment of myasthenia gravis according to clinical subtype.
Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Nagane Y BMC Neurol. 2016; 16(1):225.
PMID: 27855632 PMC: 5114805. DOI: 10.1186/s12883-016-0756-3.
Precision medicine in myasthenia graves: begin from the data precision.
Li H, Hong Y, Xie Y, Hao H, Sun R Ann Transl Med. 2016; 4(6):106.
PMID: 27127759 PMC: 4828738. DOI: 10.21037/atm.2016.02.16.